Review: Bioactive compounds and cellular pharmacology of Sonneratia mangroves with evidence, mechanisms, and translational gaps
Cell Biology and Development · 30.06.2026 · 10 (1)
DOI: 10.13057/cellbioldev/v100102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology and Development, online erschienen am 30.06.2026. Verfasst von MARISCA SETYANINGRUM und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Setyaningrum M, Afriawan MDAA, Andira MHP, Izdihar NS, Sulton MN, Praptiwi, Setyawan AD. 2026. Review: Bioactive compounds and cellular pharmacology of Sonneratia mangroves with evidence, mechanisms, and translational gaps. Cell Biol Dev 10 (1): v100102. https://doi.org/10.13057/cellbioldev/v100102. Sonneratia mangroves are consumed as foods and used in traditional medicine, yet evidence for their cellular pharmacology ranges from cell-free chemical assays to heterogeneous preclinical models. This structured narrative review critically appraised phytochemical, biochemical, cell-based, and animal studies of S. alba, S. caseolaris, S. ovata, and S. apetala through June 2026, emphasizing botanical authentication, chemical definition, model relevance, and strength of mechanistic inference. Phenolic acids, flavonoids, triterpenoids, sterols, and related metabolites recur across the genus, but composition varies with organ, solvent, provenance, and analytical method. Most reports remain Level 1 evidence, whereas validated cellular and target-based studies are comparatively scarce. The most coherent cross-model chain involves a standardized S. apetala fruit extract that inhibited human neutrophil elastase (IC50 371.8±3.73 ng/mL), reduced epithelial injury, and showed activity in a mouse lung-injury model. Luteolin-7-O-beta-glucoside from S. caseolaris also reduced melanin formation while maintaining cell viability. Major constraints are incomplete voucher documentation, inconsistent extract standardization, limited target validation, uncertain exposure, and scarce independent replication. No human clinical evidence was identified. Future development should prioritize authenticated material, quantitative chemical fingerprints, physiologically relevant dosing, orthogonal cellular assays, pharmacokinetics, and early safety testing before therapeutic claims are advanced.
Zitieren
APA
SETYANINGRUM, M., AFRIAWAN, M. D. A. A., ANDIRA, M. H. P., IZDIHAR, N. S., SULTON, M. N., PRAPTIWI, P., & SETYAWAN, A. D. (2026). Review: Bioactive compounds and cellular pharmacology of Sonneratia mangroves with evidence, mechanisms, and translational gaps. Cell Biology and Development, 10(1). https://doi.org/10.13057/cellbioldev/v100102
Vancouver
SETYANINGRUM M, AFRIAWAN MDAA, ANDIRA MHP, IZDIHAR NS, SULTON MN, PRAPTIWI P, et al. Review: Bioactive compounds and cellular pharmacology of Sonneratia mangroves with evidence, mechanisms, and translational gaps. Cell Biology and Development. 2026;10(1). doi:10.13057/cellbioldev/v100102
BibTeX
@article{SETYANINGRUM2026,
author = {SETYANINGRUM, MARISCA and AFRIAWAN, MUHAMMAD DYMAS AUSHAF AQIL and ANDIRA, MUHAMMAD HANIFTA PRIA and IZDIHAR, NISRINA SHOFI and SULTON, MUHAMMAD NUR and PRAPTIWI, PRAPTIWI and SETYAWAN, AHMAD DWI},
title = {Review: Bioactive compounds and cellular pharmacology of Sonneratia mangroves with evidence, mechanisms, and translational gaps},
journal = {Cell Biology and Development},
year = {2026},
volume = {10},
number = {1},
doi = {10.13057/cellbioldev/v100102}
}
EUVIMED